Carelon Research

Dec 9, 2024 | healtheconomics.com | Michael Grabner |Carelon Research |Hayleigh Culliton

Written by: Michael Grabner, PhD, Principal Scientist, Carelon ResearchInterest in the use of real-world data (RWD) and real-world evidence (RWE) for regulatory and insurance coverage decision-making in the US has increased substantially over the past decade.1-3 The US Food and Drug Administration’s (FDA) RWE framework has catalyzed the generation and integration of RWE for pharmaceuticals and medical devices.

Mar 26, 2024 | diabetesjournals.org | Carelon Research

OBJECTIVETo assess risk of anaphylaxis among patients with type 2 diabetes mellitus who are initiating therapy with a glucagon-like peptide 1 receptor agonist (GLP-1 RA), with a focus on those starting lixisenatide therapy. RESEARCH DESIGN AND METHODSA cohort study was conducted in three large, U.S. claims databases (2017–2021).

Jan 13, 2024 | link.springer.com | Carelon Research |San Antonio

AbstractEPOCH-US is an ongoing, retrospective, observational cohort study among individuals identified in the Healthcare Integrated Research Database (HIRD®) with ≥ 12 months of continuous health plan enrollment.

Nov 4, 2023 | news-journal.com | Carelon Research

Boehringer Ingelheim and Carelon Research have conducted the first large-scale U.S. validation of a new AI-driven tool for chronic kidney disease (CKD) The Klinrisk model predicted disease progression in over 80% of individuals at all stages of the disease, based on data from a diverse population of over 4 million U.S. adults Validated tools to estimate risk are needed for the more than 35 million adults living with CKD in the U.S.RIDGEFIELD, Conn. and WILMINGTON, Del.